WaveMan
WaveMan · Company
ANNX · Annexon, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ANNX Annexon (ANNX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001528115
Quote by TradingView
Cluster · 3 insidersC-suite buying · 1Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
111
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $56.7K priced

What the filings say about ANNX

Insiders, 180 days
+$3.5M net bought
3 buyers
Planned sales (Form 144), 90 days
$10.6K
1 notice

Annexon insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Annexon, Inc. insiders bought a net $3.5M of stock across 80 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Love Douglas
PRESIDENT AND CEO
BUY
2026-09-25 SECtraded 2026-09-24
26,065
$99.8K
-7.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Feb 13, 2025.
  • The trade is 6.7% of the 390,476 shares held after it.
  • No other insider bought within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Love Douglas bought about $99.8K of ANNX on Sep 24, 2026; 111 funds added in the latest 13F quarter.
Satter Muneer A
Director
BUY
2026-05-29 SECtraded 2026-05-28
613,497
$3.3M
-33.7%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Nov 21, 2025.
  • +37.4% median (+35.7% mean) 90-day return after 8 previous buys.
  • The trade is 5.9% of the 10,342,134 shares held after it.
  • 1 other insider bought within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Satter Muneer A bought about $3.3M of ANNX on May 28, 2026, the largest insider purchase at the company since 2023; 1 other insider bought within 30 days and 111 funds added in the latest 13F quarter.
Carson William H.
Director
BUY
2026-05-13 SECtraded 2026-05-11
8,000
$46.2K
-31.1%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (17 buys), the last on Apr 10, 2026.
  • +18.1% median (+20.9% mean) 90-day return after 17 previous buys.
  • The trade is 10.2% of the 78,405 shares held after it.
  • 1 other insider bought within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Carson William H. bought about $46.2K of ANNX on May 11, 2026; 1 other insider bought within 30 days and 111 funds added in the latest 13F quarter.
Carson William H.
Director
BUY
2026-04-14 SECtraded 2026-04-10
8,000
$49.6K
-41.7%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 buys), the last on Mar 10, 2026.
  • +20.9% median (+22.1% mean) 90-day return after 16 previous buys.
  • The trade is 11.4% of the 70,405 shares held after it.
  • No other insider bought within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Carson William H. bought about $49.6K of ANNX on Apr 10, 2026; 111 funds added in the latest 13F quarter.
Carson William H.
Director
BUY
2026-03-12 SECtraded 2026-03-10
8,000
$45.4K
-34.6%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Dec 30, 2025.
  • +23.6% median (+24.6% mean) 90-day return after 15 previous buys.
  • The trade is 12.8% of the 62,405 shares held after it.
  • No other insider bought within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Carson William H. bought about $45.4K of ANNX on Mar 10, 2026; 111 funds added in the latest 13F quarter.
80 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 75 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$3.5M over 180 days
+$99.8K over 90 days
more than 93% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
111 funds bought in last quarter
more than 72% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
19.6% of the float short (float per yahoo 2026-10-26) · 8.9 days to cover · settled 2026-09-30
The situation: each line is one rule over one dataset
3 insiders bought a net $3.5M while the stock fell 39% over six months, but 1 Form 144 notice ($10.6K) are queued to sell.
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ANNX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+23.3%12M
-11%+37%+84%+132%2025-102025-122026-022026-042026-062026-082026-10 2026-05-28 · Satter Muneer A bought $3.3M2025-11-19 · Satter Muneer A bought $2.0M2025-11-21 · Satter Muneer A bought $1.8M2025-11-20 · Satter Muneer A bought $1.8M2025-11-18 · Satter Muneer A bought $1.6M2025-11-17 · Satter Muneer A bought $1.5M2025-12-01 · Choi Jung bought $138.3K2026-09-24 · Love Douglas bought $99.8K2026-04-10 · Carson William H. bought $49.6K2026-05-11 · Carson William H. bought $46.2K2026-03-10 · Carson William H. bought $45.4K2026-02-18 · Yednock Ted sold $40.1K2026-02-18 · Lew Jennifer sold $40.1K2026-03-02 · ARTIS DEAN RICHARD sold $32.0K2026-02-18 · Overdorf Michael sold $31.7K2026-03-02 · Dananberg Jamie sold $31.6K2026-03-02 · Yednock Ted sold $30.2K2026-03-02 · Lew Jennifer sold $30.2K2026-02-18 · ARTIS DEAN RICHARD sold $27.0K2026-02-18 · Dananberg Jamie sold $27.0K2026-03-02 · Overdorf Michael sold $23.5K2025-12-30 · Carson William H. bought $20.7K2025-12-01 · Carson William H. bought $18.4K2025-10-30 · Carson William H. bought $13.0K2026-08-13 · WIGGANS THOMAS G filed to sell $10.6K2026-07-15 · WIGGANS THOMAS G filed to sell $12.6K2026-07-14 · WIGGANS THOMAS G filed to sell $5.6K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ANNX: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
19,518,496 sh
$111.5M
BlackRock, Inc.
13,539,744 sh
$77.3M
Redmile Group, LLC
11,869,877 sh
$67.8M
STATE STREET CORP
9,824,321 sh
$56.1M
BVF INC/IL
8,698,173 sh
$49.7M

Congress trades in ANNX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ANNX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
WIGGANS THOMAS G
Filed 2026-08-13
$10.6K
WIGGANS THOMAS G
Filed 2026-07-15
$12.6K
WIGGANS THOMAS G
Filed 2026-07-14
$5.6K

ANNX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$336.2K position · as of 2026-07-31
0.7%
Select Biotechnology Portfolio
$27.5M position · as of 2026-05-31
0.5%
Fidelity Advisor Biotechnology Fund
$8.5M position · as of 2026-07-31
0.4%
NORTH SQUARE KENNEDY MICROCAP FUND
$125.2K position · as of 2026-05-31
0.4%
Select Pharmaceuticals Portfolio
$5.4M position · as of 2026-05-31
0.4%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$35.6M position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
11 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
0 active
4
Phase 2
0 active
4
Phase 3
3 active
What changed recently
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in
2026-10-20 · Completion moved 2026-12-31 → 2027-05-31
Phase 3
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonapr
2026-10-07 · Completion moved 2026-10-31 → 2027-07-31
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $3.5M bought by insiders over 180 days, 111 funds added last quarter, $10.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ANNX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$193.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-105.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-79.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-97.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-135.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$216.4M-$154.1M-$143.7M-$145.6M
Net income-$206.7M-$138.2M-$134.2M-$141.9M
EPS (diluted)-1.34-1.01-1.77-2.60
Operating cash flow-$186.4M-$118.0M-$121.1M-$116.3M
Cash$162.1M$49.5M$225.1M$140.0M
SEC XBRL, fiscal years, as known on 2026-10-27

ANNX Stock Sonar score 4/7 axes

Find similar shapesCompare

ANNX ranks highest on insider conviction (91st percentile) and institutional and government (72nd), and lowest on risk and compliance (16th), among Pharma & Biotech peers.

Profitability
29
Inputs
  • Return on equity-105.3% · 32 pct, sector of 545
  • Return on assets-79.4% · 30 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-97.6% · 26 pct, sector of 576
Insider conviction
91
Inputs
  • Net Form 4 buying (codes P and S), 180d$3.5M · 93 pct, sector of 428
  • Insider buyers, 180d3 · 89 pct, sector of 437
Institutional and government
72
Inputs
  • Funds adding, latest quarter111 · 72 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
16
Inputs
  • Short interest, % of float+19.6% · 16 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ANNX filings, in plain words

Are Annexon insiders buying or selling ANNX?

In the 180 days to 2026-10-27, Annexon insiders were net buyers, a net $3.5M across purchases and sales reported on Form 4, by 3 buyers.

Are there planned insider sales of ANNX?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $10.6K of stock; the latest, by WIGGANS THOMAS G, was filed 2026-08-13.

Read the full summary

In the 180 days to 2026-10-27, Annexon insiders were net buyers of ANNX, a net $3.5M across purchases and sales reported on Form 4 by 3 buyers. 3 insiders reported purchases in that window. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $10.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies